NCT06726369View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Advanced Solid Tumors
Interventions
DRUG

MK-6204 (SKB535) for Injection

MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

Trial Locations (7)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

410031

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

Unknown

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

NOT_YET_RECRUITING

Chongqing University Cancer Hospital, Chongqing

NOT_YET_RECRUITING

Fujian Provincial Cancer Hospital, Fuzhou

NOT_YET_RECRUITING

Shanghai East Hospital, Shanghai

NOT_YET_RECRUITING

Hubei Cancer Hospital, Wuhan

All Listed Sponsors
lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY